Processa Pharmaceuticals Stock (NASDAQ:PCSA)
Previous Close
$0.90
52W Range
$0.90 - $17.40
50D Avg
$1.27
200D Avg
$1.78
Market Cap
$2.97M
Avg Vol (3M)
$65.69K
Beta
0.60
Div Yield
-
PCSA Company Profile
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
PCSA Performance
Peer Comparison
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
FRTX | Fresh Tracks Therapeutics, Inc. |
IKT | Inhibikase Therapeutics, Inc. |
SABS | SAB Biotherapeutics, Inc. |
ACXP | Acurx Pharmaceuticals, Inc. |
INBX | Inhibrx Biosciences, Inc. |
FENC | Fennec Pharmaceuticals Inc. |
SCPS | Scopus BioPharma Inc. |
AKTX | Akari Therapeutics, Plc |
ANTX | AN2 Therapeutics, Inc. |
THRD | Third Harmonic Bio, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
CELC | Celcuity Inc. |
MACK | Merrimack Pharmaceuticals, Inc. |
ELVN | Enliven Therapeutics, Inc. |
ELYM | Eliem Therapeutics, Inc. |